	US 11,872,230 B2
	Method of treating a methionine-dependent cancer
Zhenxun Wang, Singapore (SG); Wai Leong Tam, Singapore (SG); Lian Yee Yip, Singapore (SG); Ying Swan Ho, Singapore (SG); Zhengwei Wu, Singapore (SG); and Bing Lim, Singapore (SG)
Assigned to Agency for Science, Technology and Research, Singapore (SG)
Filed by Agency for Science, Technology and Research, Singapore (SG)
Filed on May 16, 2022, as Appl. No. 17/745,292.
Application 17/745,292 is a continuation of application No. 16/039,916, filed on Jul. 19, 2018, granted, now 11,376,256.
Prior Publication US 2022/0280520 A1, Sep. 8, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6886 (2018.01); A61K 31/52 (2006.01); A61P 35/04 (2006.01); A61K 31/7105 (2006.01); A61K 31/67 (2006.01)

CPC A61K 31/52 (2013.01) [A61K 31/67 (2013.01); A61K 31/7105 (2013.01); A61P 35/04 (2018.01); C12Q 1/6886 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01)]

4 Claims

1. A method of treating cancer or reducing the risk of recurrence of cancer in a subject; the method comprising the steps of:

a) detecting increased expression levels of methionine adenosyltransferase 2A (MAT2A), methylthioadenosine phosphorylase (MTAP) and cluster of differentiation (CD166) biomarkers in a cancer specimen obtained from the subject,

b) identifying the subject as one who is suitable for treatment with a methionine-cycle inhibitor when the expression levels of the biomarkers in the cancer specimen are increased as compared to the expression levels of the biomarkers in a non-cancerous specimen; and

c) administering a methionine cycle inhibitor to the subject when the subject is identified as one who is suitable for treatment with the methionine-cycle inhibitor, so as to treat cancer or reduce the risk of recurrence of cancer in the subject,

wherein the methionine-cycle inhibitor is a MAT2A inhibitor, D9, methotrexate or anti-folate.